Several months after the FDA signed off on Bimzelx’s label expansion into hidradenitis suppurativa (HS), UCB is expanding an existing campaign to include the drug’s new indication. UCB ...

UCB presents latest research advancements at European Pediatric Neurology Society Congress 15 scientific abstracts, including three oral presentations demonstrate UCB’s continued commitment to leading ...

Partnering to innovate: UCB pharma Mark Bodmer and Jonathan Lewis of UCB pharma talk us though the partnering model at UCB, and how partnering can drive innovation.

UCB has three products currently in phase III which are due to produce pivotal results in the next few years: brivaracetam for epilepsy, lupus treatment epratuzumab and romosozumab for osteoporosis.

Access UCB stock price history with daily data, historical prices, all-time highs, and stock chart history. Download and analyze trends easily.

After 18 months of planning and collaboration, Lake Catholic High School is launching a rebranded identity that includes new academic and athletic logos and a refined school seal. According to a sc… ...

DelveInsight's Cancer Cachexia Market Insights report includes a comprehensive understanding of current treatment practices, cancer cachexia emerging drugs, market share of individual therapies, and ...

From Atol protected to Abtot, IATA to Abta, holiday company and airline websites are plastered with an alphabet soup of logos and badges. Some tell you that your rights and money are protected by the ...

The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate (ACM-001.1) ...